Clinical development of chimeric antigen receptor-T cell therapy for hematological malignancies.
10.1097/CM9.0000000000002549
- Author:
Zhihuan YANG
1
;
Ying WANG
Author Information
1. State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Tianjin Key Laboratory of Cell Therapy for Blood Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300020, China.
- Publication Type:Journal Article
- MeSH:
Humans;
Receptors, Chimeric Antigen;
Receptors, Antigen, T-Cell/genetics*;
Immunotherapy, Adoptive/adverse effects*;
Hematologic Neoplasms/therapy*;
Multiple Myeloma/etiology*;
Cell- and Tissue-Based Therapy
- From:
Chinese Medical Journal
2023;136(19):2285-2296
- CountryChina
- Language:English
-
Abstract:
Cellular therapies have revolutionized the treatment of hematological malignancies since their conception and rapid development. Chimeric antigen receptor (CAR)-T cell therapy is the most widely applied cellular therapy. Since the Food and Drug Administration approved two CD19-CAR-T products for clinical treatment of relapsed/refractory acute lymphoblastic leukemia and diffuse large B cell lymphoma in 2017, five more CAR-T cell products were subsequently approved for treating multiple myeloma or B cell malignancies. Moreover, clinical trials of CAR-T cell therapy for treating other hematological malignancies are ongoing. Both China and the United States have contributed significantly to the development of clinical trials. However, CAR-T cell therapy has many limitations such as a high relapse rate, adverse side effects, and restricted availability. Various methods are being implemented in clinical trials to address these issues, some of which have demonstrated promising breakthroughs. This review summarizes developments in CAR-T cell trials and advances in CAR-T cell therapy.
